UPDATE 1-Antigenics cancer vaccine gets negative EU panel vote

* Says withdrawing marketing application

* Will evaluate re-filing at later date * Shares down 6 pct

Nov 20 (Reuters) - Antigenics Inc AGEN.O said an advisory committee of European health regulators formally rejected its application to market a potential cancer vaccine, Oncophage, and that it would withdraw the filing.

However, the company said it would evaluate other options for Oncophage such as re-filing the application at a later date.

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had informed the company of its decision verbally earlier in October. [ID:nBNG412356]

Antigenics has been seeking a partner on the potential vaccine, which would have been the first to receive a marketing licence to treat kidney cancer in the European Union if approved.

The company said it would investigate Oncophage in other cancer forms “with a strict focus on working efficiently and preserving capital.”

Oncophage has fast track and orphan drug designations from the U.S. Food and Drug Administration for both kidney cancer and metastatic melanoma.

Antigenics shares were down 6 percent at $0.90 Friday on Nasdaq. (Reporting by Vidya L Nathan in Bangalore; Editing by Aradhana Aravindan)